According to Jefferies, Exact Sciences EXAS collaborator Dr. David Ahlquist of the Mayo Clinic presented initial data from the first head-to-head pilot study comparing EXAS' Cologuard stool-based DNA (sDNA) test with ARUP Labs' blood-based Septin9 assay.
Jefferies said that the study, which was conducted in a blinded fashion at Mayo, involved 22 pre-cancerous polyps or adenoma samples (median size: ~2cm) and 30 colorectal cancer samples (median size: ~5cm). “Initial results demonstrated only 14% sensitivity for Septin9 compared to ~82% for Cologuard for detection of advanced adenoma at 90% specificity. For cancerous polyp detection, Septin9 demonstrated a sensitivity of ~60% compared to 87% for Cologuard. The data should alleviate concerns around the competitive viability of EXAS' sDNA technology relative to Septin9, in our view.”
Exact Sciences closed yesterday at $7.50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in